Litcius/Paper detail

Acquisition of a Stable and Transferable blaNDM-5-Positive Plasmid With Low Fitness Cost Leading to Ceftazidime/Avibactam Resistance in KPC-2-Producing Klebsiella pneumoniae During Treatment

Jiangqing Huang, Shengcen Zhang, Zhichang Zhao, Min Chen, Yingping Cao, Bin Li

2021Frontiers in Cellular and Infection Microbiology29 citationsDOIOpen Access PDF

Abstract

The emergence and prevalence of carbapenem-resistant Enterobacteriaceae (CRE) have drawn worldwide attention. Ceftazidime/avibactam (CAZ/AVI) gives us a valuable alternative strategy to treat CRE infections. Unfortunately, CAZ/AVI resistance could occur during CAZ/AVI treatment. The CAZ/AVI-resistant Carbapenem-resistant Klebsiella pneumoniae (CR-KP) (KP137060) and earlier CAZ/AVI-susceptible isolate (KP135194) from the same hospitalized patient were collected at Fujian Medical University Union Hospital between October and November 2019. In this study, CAZ/AVI MICs of CAZ/AVI-susceptible and -resistant isolates (KP135194 and KP137060) were 4 mg/L and 128 mg/L, respectively; and the two isolates had the same antibiotic resistance pattern to other carbapenems. Two strains were then submitted for whole-genome sequencing and bioinformatic analysis. ompK36 was not detected in two isolates. No mutation was observed in bla KPC-2 , ompK35 and ompK37 in this study and there was no significant difference of the expression in bla KPC-2 , ompK35 and ompK37 between the two isolates ( p >0.05). Two isolates were sequence type 11 and harbored bla KPC-2 , bla SHV-182 and bla TEM-1B . Compared with KP135194, KP137060 harbored an additional bla NDM-5 positive plasmid. bla NDM-5 gene could be successfully transferred into E. coli J53 at a conjugation frequency of 1.14×10 -4 . Plasmid stability testing showed that bla KPC-2 - and bla NDM-5 -harboring plasmids were still stably maintained in the hosts. Growth assay and growth competition experiments showed there was no significant difference in fitness cost between two CR-KP isolates. Our study described the acquisition of a bla NDM-5 -harboring plasmid leading to resistance to ceftazidime/avibactam in KPC-2-producing Klebsiella pneumoniae during treatment. This phenomenon deserves further exploration.

Topics & Concepts

Klebsiella pneumoniaeCeftazidime/avibactamPlasmidMicrobiologyBiologyCeftazidimeEnterobacteriaceaeAntibiotic resistanceAntibioticsCarbapenemGeneEscherichia coliBacteriaGeneticsPseudomonas aeruginosaAntibiotic Resistance in BacteriaPharmaceutical and Antibiotic Environmental ImpactsBacterial Identification and Susceptibility Testing
Acquisition of a Stable and Transferable blaNDM-5-Positive Plasmid With Low Fitness Cost Leading to Ceftazidime/Avibactam Resistance in KPC-2-Producing Klebsiella pneumoniae During Treatment | Litcius